In the 1980s, after decades of steadily declining rates of tuberculosis, ambitious plans were
made to eliminate the disease in the United States. Despite these plans, the control of …

The past decade has seen an explosive increase in the development of potential new
tuberculosis vaccine candidates, as well as the establishment of at least two testing centers …

Abstract During 1993-2003, incidence of tuberculosis (TB) in the United States decreased
44% and is now occurring at a historic low level (14,874 cases in 2003). The Advisory …

An estimated one third of the world's population is infected with Mycobacterium tuberculosis,
and nearly 9 million persons develop disease caused by M. tuberculosis each year …

The high incidence of tuberculosis around the world and the inability of BCG to protect
certain populations clearly indicate that an improved vaccine against tuberculosis is needed …

Developing effective tuberculosis (TB) vaccines is a high priority. We use mathematical
models to predict the potential public health impact of new TB vaccines in high-incidence …

Mycobacterium tuberculosis infection in non-human primates parallels human tuberculosis,
and provides a valuable vaccine evaluation model. However, this model is limited by the …

Mycobacterium tuberculosis heat shock protein 16.3 (MTB HSP 16.3) accumulates as the
dominant protein in the latent stationary phase of tuberculosis infection. MTB HSP 16.3 …

The association of genetic variants of chemokines, CCL2 [MCP-1 (monocyte
chemoattractant protein-1)], CCL5 [RANTES (regulated on activation, normal T-cell …

The growing pandemic of human tuberculosis has not been affected significantly by the
widespread use of the only currently available vaccine, bacille Calmette Guerin. Bacille …